Interferon epsilon and ovarian cancer

Samar Elorbany; Beatrice Malacrida; Frances Balkwill

doi:10.1016/j.trecan.2023.09.008

Interferon epsilon and ovarian cancer

Trends Cancer. 2023 Dec;9(12):985-986. doi: 10.1016/j.trecan.2023.09.008. Epub 2023 Sep 29.

Authors

Samar Elorbany¹, Beatrice Malacrida¹, Frances Balkwill²

Affiliations

¹ Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, UK.
² Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: f.balkwill@qmul.ac.uk.

PMID: 37778961
DOI: 10.1016/j.trecan.2023.09.008

Abstract

Most biologists know of the interferons IFNα, IFNβ, and IFNγ and their roles in immunity and infection, but they may not have heard of IFNε. A recent study in Nature suggests that IFNε can act as a tumor suppressor in serous ovarian cancers.

Keywords: interferon; interferon epsilon; ovarian cancer; tumor suppressor; type I interferon.

MeSH terms

Female
Humans
Interferons* / metabolism
Ovarian Neoplasms* / immunology

Substances

IFNE protein, human
Interferons

Grants and funding

25714/CRUK_/Cancer Research UK/United Kingdom